What it does / how it works
A triple agonist stacked on a dual agonist. No trial starts at the 20+40 mg stock ratio. Separate titration is the safer design.
| Class | Blend · RET60 · 20 mg + 40 mg |
| Typical vial | 60 mg stock |
| Reconstitution | If mixed, 6 mL BAC. Reta 3.33 mg/mL, Tirz 6.67 mg/mL. |
| Storage after mix | 2–8°C, use within 28 days |
Protocol
| Goal | Dose | How often | How long | Route |
| Weeks 1-4 | Retatrutide 1 mg + Tirzepatide 2 mg | Once weekly | 4 weeks | SubQ |
| Weeks 5-8 | Retatrutide 2 mg + Tirzepatide 4 mg | Once weekly | 4 weeks | SubQ |
| Stock only | 20 mg + 40 mg | Never | Not a dose | — |
Watch: Highest-risk metabolic blend if treated as one injection.